Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada

Thumbnail image

Download files

DOI

https://doi.org/10.1097/qad.0000000000003680

Language of the publication
English
Date
2023-10-01
Type
Article
Author(s)
  • Costiniuk, Cecilia T.
  • Singer, Joel
  • Lee, Terry
  • Galipeau, Yannick
  • McCluskie, Pauline S.
  • Arnold, Corey
  • Langlois, Marc-André
  • Needham, Judy
  • Jenabian, Mohammad-Ali
  • Burchell, Ann N.
  • Samji, Hasina
  • Chambers, Catharine
  • Walmsley, Sharon
  • Ostrowski, Mario
  • Kovacs, Colin
  • Tan, Darrell H. S.
  • Harris, Marianne
  • Hull, Mark
  • Brumme, Zabrina L.
  • Lapointe, Hope R.
  • Vulesevic, Branka
  • Brockman, Mark A.
  • Margolese, Shari
  • Mandarino, Enrico
  • Samarani, Suzanne
  • Lebouché, Bertrand
  • Angel, Jonathan B.
  • Routy, Jean-Pierre
  • Cooper, Curtis L.
  • Anis, Aslam H.
  • COVAXHIV Study Group
Publisher
Wolters Kluwer Health, Inc.

Abstract

Objectives: Many vaccines require higher/additional doses or adjuvants to provide adequate protection for people with HIV (PWH). Here, we compare coronavirus disease 2019 (COVID-19) vaccine-induced antibody neutralization capacity in PWH vs. HIV-negative individuals following two vaccine doses.

Design: In Canadian prospective observational cohorts, including a multicentre study of PWH receiving at least two COVID-19 vaccinations (mRNA or ChAdOx1-S), and a parallel study of HIV-negative controls (Stop the Spread Ottawa Cohort), we measured vaccine-induced neutralization capacity 3 months post dose 2 (±1 month).

Methods: COVID-19 neutralization efficiency was measured by calculating the half maximal inhibitory dilution (ID50) using a high-throughput protein-based neutralization assay for Ancestral (Wuhan), Delta and Omicron (BA.1) spike variants. Univariable and multivariable quantile regression were used to compare COVID-19-specific antibody neutralization capacity by HIV status.

Results: Neutralization assays were performed on 256 PWH and 256 controls based on specimen availability at the timepoint of interest, having received two vaccines and known date of vaccination. There was a significant interaction between HIV status and previous COVID-19 infection status in median ID50. There were no differences in median ID50 for HIV+ vs. HIV-negative persons without past COVID-19 infection. For participants with past COVID-19 infection, median ICD50 was significantly higher in controls than in PWH for ancestral SARS-CoV-2 and Omicron variants, with a trend for the Delta variant in the same direction.

Conclusion: Vaccine-induced SARS-CoV-2 neutralization capacity was similar between PWH vs. HIV-negative persons without past COVID-19 infection, demonstrating favourable humoral-mediated immunogenicity. Both HIV+ and HIV-negative persons demonstrated hybrid immunity.

Subject

  • Health,
  • Coronavirus diseases

Rights

Pagination

F25-F35

Peer review

Yes

Open access level

Gold

Identifiers

PubMed ID
37534695
ISSN
0269-9370

Article

Journal title
AIDS
Journal volume
37
Journal issue
12

Sponsors

This project was supported by funding from the Public Health Agency of Canada, through the Vaccine Surveillance Reference group and the COVID-19 Immunity Task Force (grant number: 2122-HQ-000075) and the CTN (grant number: N/A). Production of COVID-19 reagents was financially supported by NRC's Pandemic Response Challenge Program.

Download(s)

URI

Collection(s)

Communicable diseases

Full item page

Full item page

Page details

Date modified: